Notably, the A + EC group also showed a decreasing trend in the selection of subsequent immunotherapy (16.73% vs. 21.46%) and targeted therapy (21.22% vs. 29.55%).
← all excerpts
Cost-effectiveness of benmelstobart and anlotinib plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer in China.
1
—
—